Press Releases Year None202020192018201720162015 Oct 12, 2020 Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress Sep 30, 2020 Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies Sep 11, 2020 Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference Aug 25, 2020 Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock Aug 25, 2020 Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
